Cargando…
Novel Target Study to Cure Cardiovascular Disease regarding Proprotein Converse Subtilisin/Kexin Type 9
OBJECTIVE: This study is aimed at screening the potential ideal lead compounds from natural drug library (ZINC database), which had potential inhibition effects against proprotein converse subtilisin/kexin type 9 (PCSK9), and contributing to enrich the practical basis of PCSK9 inhibitor screening. M...
Autores principales: | Zhao, Yingjing, Li, Weihang, Li, Weiye, Tao, Hong, Li, Yuting, Wu, Bo, Wang, Xinhui, Zhou, Huasong, Gao, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578827/ https://www.ncbi.nlm.nih.gov/pubmed/36267835 http://dx.doi.org/10.1155/2022/9039377 |
Ejemplares similares
-
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020) -
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022) -
The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
por: Kim, Eun Ji, et al.
Publicado: (2020) -
Corrigendum to: Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Publicado: (2021)